Pure Global
NCT06420986

Open Hemorrohoidectomy Versus Transanal Hemorrhoidal Desarterialization in Hemorrhoids Grade III: The Effect on Symptons: An Open-label Randomized Controlled Trial

Hospital Son Llatzer·ClinicalTrials.gov·procedureCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hemorrhoids Third Degree
Drug/Device/Intervention
Open Hemorrhoidectomy
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Hospital Son Llatzer
Location
Palma De Mallorca, Spain
Timeline & enrollment
Phase
N/A
Start date
Aug 12, 2021
End date
Apr 17, 2024
Enrollment
50 participants
Primary outcome

hemorrhoidal disease symptom score,short health scale in hemorrhoidal disease

Summary

The goal of this clinical trial is to learn if open hemorroidectomy diminishes symptoms
 compared to transanal hemorrhoidal desarterialization (THD) in patients presenting with
 hemorrhoids grade III. The main question it aims to answer is:
 
 - Do patients undergoing open hemorroidectomy present with lesser symptoms 1 year after
 surgery, compared to those undergoing a THD?
 
 Researchers will compare open hemorroidectomy to THD in terms of symptom response one year
 after the procedure.
 
 Participants will:
 
 - Undergo surgical treatment of hemorroids performed by one of the two techniques: open
 hemorroidectomy versus THD.
 
 - Fill in symptom forms before and one year after the surgical procedure.
 
 - Attend control visits one week, one month, three months and one year after the surgical
 procedure.

ICD-10 classifications
Third degree haemorrhoidsFourth degree haemorrhoidsSecond degree haemorrhoidsFirst degree haemorrhoidsThird-stage haemorrhage
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06420986
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06420986 through Pure Global AI's free database. This phase not specified trial is sponsored by Hospital Son Llatzer and is currently Completed. The study focuses on Hemorrhoids Third Degree. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.